Skip to main content
IONIS PHARMACEUTICALS INC logo

IONIS PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · IONS ISIN · US4622221004 LEI · 549300SI4ZGLG0BLUZ92 US Manufacturing
Open in API
Filings indexed 1,797 across all filing types
Latest filing 2022-04-14 Director's Dealing
Country US United States of America
Listing US IONS

About IONIS PHARMACEUTICALS INC

https://www.ionis.com/

Ionis Pharmaceuticals, Inc. is a biopharmaceutical company that discovers and develops RNA- and DNA-targeted therapeutics. Leveraging its expertise in antisense technology and a deep understanding of genetics, the company creates novel medicines designed to treat a wide range of serious diseases. Its development pipeline and marketed products primarily address neurologic and cardiometabolic disorders, as well as other areas with high unmet patient needs, including rare diseases. The company's approach aims to provide new solutions for complex and often intractable conditions by targeting the root cause of disease at the genetic level.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2022-04-14 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-04-11 English
PRIMARY DOCUMENT
Director's Dealing
2022-04-05 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content focuses on the amendment and restatement of the company's Change of Control and Severance Benefit Plan affecting executive officers. This is an announcement related to management compensation arrangements and changes in executive benefits, not a full annual or quarterly report, earnings release, or other financial statement. The key item is Item 5.02, which pertains to departure or appointment of directors or officers and related compensatory arrangements. This fits best under Board/Management Information (MANG) as it involves changes and updates related to senior management and their compensation plans. The document length (6318 characters) and detailed description confirm it is not a brief announcement or a certification but a substantive filing about management arrangements. Therefore, the classification is MANG with high confidence.
2022-03-18 English
PRIMARY DOCUMENT
Director's Dealing
2022-03-02 English
PRIMARY DOCUMENT
Director's Dealing
2022-03-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.